On the other hand, for papillary adenocarcinoma and moderately differentiated tubular adenocarcinoma, the proportions of HER2-positive patients were numerically higher than those for FGFR2-positive patients (Fig. 2B). This evidence concerns the gene FGFR2 and papillary adenocarcinoma.